In cases of the APPL2-RAF1 fusion, RAF1 inhibitor use is recommended if metastatic relapse occurs, because the fusion was continuously detected from three recurrence and metastatic tumors after the initial tumor was identified. Here, RAF1 is linked to metastatic neoplasm.